Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note released on Friday morning. The brokerage issued a sell rating on the stock.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $0.19 on Friday. The stock has a fifty day moving average price of $0.16 and a 200 day moving average price of $1.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock has a market cap of $35.45 million, a PE ratio of 0.00 and a beta of 2.06. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Sell-side analysts forecast that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.